Pancragen (50mg)

What is Pancragen (50 mg)?

Pancragen (50 mg) is a synthetic tetrapeptide bioregulator with the sequence Lys–Glu–Asp–Trp (KEDW). It is described as a pancreas-associated regulatory peptide and is commonly categorized within organ-specific and bioregulator peptides.

Most studies focus on pancreatic systems, as the peptide has been investigated in models related to pancreatic endocrine and exocrine function, metabolic regulation, and cellular homeostasis.

In laboratory research, Pancragen (also known as Pancragen bioregulator) is used to explore how short peptides may influence pancreatic gene expression, cell differentiation markers, and key signaling pathways under strictly preclinical conditions.

Product Specifications

• Peptide Sequence: Lys–Glu–Asp–Trp (KEDW)
• Chemical Formula: C₂₆H₃₆N₆O₉
• Molecular Weight: 576.25 g/mol
• Purity: Research-grade, typically ≥98–99% by HPLC; identity and purity confirmed by chromatographic and mass-spectrometric methods, with lot data provided in a COA
• Packaging Format: 50 mg lyophilized (freeze-dried) peptide in a sealed vial, suitable for multi-arm cell studies, animal experiments, or combined in-vitro/in-vivo workflows
• Storage Conditions: Store at −20 °C, protect from light and moisture, and avoid repeated freeze–thaw cycles
• Intended Use: For laboratory research use only; not for human or veterinary use

Key Characteristics of Pancragen (50 mg)

• Short pancreas-associated bioregulator: A KEDW tetrapeptide described in the Khavinson bioregulator literature as an endogenous regulatory sequence linked to pancreatic tissue.
• Cell-state and differentiation markers (preclinical): Investigated for effects on markers related to pancreatic cell differentiation and functional state, including features associated with both acinar and islet lineages in experimental systems.
• Broad biomarker monitoring: Preclinical studies report changes in markers connected to insulin/glucagon signaling, extracellular matrix remodeling (e.g., MMP2, MMP9), proliferation markers (PCNA, Ki67), and apoptosis-related signaling proteins—typically interpreted within transcriptional and epigenetic regulation frameworks.
• Used in bioregulator and aging research: Included in broader work examining how short peptides may influence gene expression and chromatin-linked control of organ-specific cell function.
• Consistent analytical documentation: Supplied as a sequence-defined, lyophilized peptide with supporting batch documentation (HPLC, MS) to support reproducible mechanistic and exploratory studies.

How Pancragen (50 mg) Supports Research

Pancragen (50 mg) supports research by providing a pancreas-directed peptide that researchers can apply in cell cultures or animal models to examine peptide-driven regulation of pancreatic gene expression and endocrine–exocrine function.

Furthermore, experimental studies associate Pancragen exposure with shifts in molecular markers of pancreatic differentiation, indicators linked to the glucose–insulin axis, and signaling pathways relevant to metabolic regulation in preclinical systems.

Some research frameworks also consider pancreatic endocrine function alongside circadian/diurnal regulation (for example, through melatonin-related signaling in islets). In those designs, researchers use Pancragen to study how endocrine, metabolic, and timing-related signals may interact—without implying clinical use.

Research Applications & Usage Information

• Pancreatic Cell Differentiation and Cell State: Used in pancreatic-derived cell cultures to track gene-expression profiles, protein levels, and markers of proliferation and differentiation after KEDW exposure. Researchers compare changes in acinar- versus islet-associated markers and relevant transcription factors under controlled in-vitro conditions.
• Endocrine Output and Metabolic Signaling: Use rodent and non-human primate models to evaluate changes in glucose–insulin axis biomarkers and other indicators of endocrine activity during experimental protocols. It is also studied in metabolic dysregulation models to explore relationships between peptide exposure and systemic metabolic readouts (without implying therapeutic benefit).
• Epigenetic and Transcriptional Regulation: Incorporated into studies focused on chromatin-associated regulation and transcriptional reprogramming, including aging- or stress-related experimental paradigms.
• Microvascular and Endothelial Endpoints: Used in animal studies where capillary permeability or endothelial adhesion act as downstream readouts linked to metabolic and pancreatic signaling changes.
• Circadian and Melatonin-Linked Contexts: Included in study designs examining how pancreatic endocrine markers relate to circadian regulation and melatonin-associated pathways in metabolic research models.

Note: Study variables (concentration, timing, route, formulation) must be defined by qualified investigators according to institutional and regulatory requirements. No dosing or clinical recommendations are provided or implied.

Handling and Storage Recommendations

• Store lyophilized Pancragen at −20 °C, tightly sealed, and protected from light and moisture.
• Let the sealed vial reach room temperature before opening to reduce condensation.
• Discard if appearance changes or validated storage times are exceeded.
• Use standard PPE and dispose of materials in accordance with institutional and regulatory waste procedures.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in‑vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2009;11(2):139-149. doi:10.1007/s10522-009-9249-8
2. Khavinson VKh, Gapparov MM g., Sharanova NE, Vasilyev AV, Ryzhak GA. Study of biological activity of Lys-Glu-ASP-TRP-NH2 endogenous tetrapeptide. Bulletin of Experimental Biology and Medicine. 2010;149(3):351-353. doi:10.1007/s10517-010-0944-x
3. Khavinson VKh, Gavrisheva NA, Malinin VV, Chefu SG, Trofimov EL. Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus. Bulletin of Experimental Biology and Medicine. 2007;144(4):559-562. doi:10.1007/s10517-007-0377-3
4. Kvetnoi IM, Ryzhak AP, Kostyuchek IN, Tafeev YuA. Effect of tetrapeptide pancragene on functional morphology of the pancreas in rats with experimental diabetes mellitus. Bulletin of Experimental Biology and Medicine. 2007;143(3):368-371. doi:10.1007/s10517-007-0114-y
5. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Moscow). 2015;80(3):310-322. doi:10.1134/s0006297915030062